ZA974828B - Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids. - Google Patents

Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.

Info

Publication number: ZA974828B
Authority: ZA; South Africa
Prior art keywords: nhe; normalization; medicament; inhibitors; exchanger
Prior art date: 1996-06-03

Application number

ZA9704828A

Inventor

Hans Jochen Lang

Hans-Willi Jansen

Jan-Robert Schwark

Heinz-Werner Kleemann

Oliver Jung

Hans-Ludwig Schaefer

Wolfgang Linz

Werner Kramer

Bernward Schoelkens

Eugen Falk

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-03

Filing date

1997-06-02

Publication date

1997-12-03

1997-03-26 Priority claimed from DE19712636A external-priority patent/DE19712636A1/en

1997-06-02 Application filed by Hoechst Ag filed Critical Hoechst Ag

1997-12-03 Publication of ZA974828B publication Critical patent/ZA974828B/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

ZA9704828A 1996-06-03 1997-06-02 Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids. ZA974828B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19622222A DE19622222A1 (en)	1996-06-03	1996-06-03	Use of sodium=proton exchange inhibitor
DE19712636A DE19712636A1 (en)	1997-03-26	1997-03-26	Use of inhibitor of sodium/proton exchange to treat hyperlipidaemia

Publications (1)

Publication Number	Publication Date
ZA974828B true ZA974828B (en)	1997-12-03

Family

ID=26026256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9704828A ZA974828B (en)	1996-06-03	1997-06-02	Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.

Country Status (23)

Country	Link
EP (1)	EP0918515B1 (en)
JP (1)	JP4527811B2 (en)
KR (1)	KR100511711B1 (en)
CN (1)	CN1221339A (en)
AR (1)	AR007353A1 (en)
AT (1)	ATE293965T1 (en)
AU (1)	AU722166B2 (en)
BR (1)	BR9709516A (en)
CA (1)	CA2257299A1 (en)
DE (2)	DE19622222A1 (en)
DK (1)	DK0918515T3 (en)
ES (1)	ES2241049T3 (en)
IL (1)	IL126935A0 (en)
NO (1)	NO985480L (en)
NZ (1)	NZ333095A (en)
PL (1)	PL189950B1 (en)
PT (1)	PT918515E (en)
RU (1)	RU2211032C2 (en)
SI (1)	SI0918515T1 (en)
SK (1)	SK165898A3 (en)
TR (1)	TR199802505T2 (en)
WO (1)	WO1997046226A2 (en)
ZA (1)	ZA974828B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6160134A (en) *	1997-12-24	2000-12-12	Bristol-Myers Squibb Co.	Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6011059A (en) *	1997-12-24	2000-01-04	Bristol-Myers Squibb Company	Acyl guanidine sodium/proton exchange inhibitors and method
DE19859727A1 (en) *	1998-12-23	2000-06-29	Aventis Pharma Gmbh	The use of inhibitors of the sodium-hydrogen exchanger for the manufacture of a medicament for the prevention of age-related organ dysfunctions, age-related illnesses for the prolongation of life
AU4360200A (en)	1999-04-23	2000-11-10	Bristol-Myers Squibb Company	Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
DE19945302A1 (en) *	1999-09-22	2001-03-29	Merck Patent Gmbh	Biphenyl derivatives as NHE-3 inhibitors
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
US6984645B2 (en)	2001-11-16	2006-01-10	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2856062B1 (en) *	2003-06-12	2005-11-11	Aventis Pharma Sa	3-GUANIDINOCARBONYL-HETEROCYCLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US7230007B2 (en)	2003-06-12	2007-06-12	Sanofi-Aventis Deutschland Gmbh	Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
NZ544671A (en) *	2003-06-26	2009-02-28	Biotron Ltd	Antiviral compounds and methods
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7314882B2 (en)	2005-01-12	2008-01-01	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Thiazolopyridines as cannabinoid receptor modulators
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (en)	2005-02-10	2009-05-07	Bristol-Myers Squibb Company	DIHYDROQUINAZOLINONES AS MODULATORS OF 5HT.
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7572808B2 (en)	2005-06-17	2009-08-11	Bristol-Myers Squibb Company	Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en)	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (en)	2005-10-26	2007-09-19	Bristol Myers Squibb Co	ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (en)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
CA2756786A1 (en)	2009-03-27	2010-09-30	Bristol-Myers Squibb Company	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
SG182662A1 (en)	2010-01-28	2012-08-30	Harvard College	Compositions and methods for enhancing proteasome activity
WO2012154967A1 (en)	2011-05-12	2012-11-15	Proteostasis Therapeutics, Inc.	Proteostasis regulators
WO2014039411A1 (en)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9849135B2 (en)	2013-01-25	2017-12-26	President And Fellows Of Harvard College	USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en)	2013-11-12	2015-05-21	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
PE20210644A1 (en)	2018-07-19	2021-03-23	Astrazeneca Ab	METHODS OF TREATMENT OF HFpEF USING DAPAGLIFLOZIN AND COMPOSITIONS INCLUDING THE SAME

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4920123A (en) *	1988-10-21	1990-04-24	Beyer Jr Karl H	Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US5110817A (en) *	1988-10-21	1992-05-05	Beyer Jr Karl H	Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
WO1991012799A1 (en) *	1990-02-28	1991-09-05	The Upjohn Company	Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
JPH06510760A (en) *	1991-08-27	1994-12-01	ジ・アップジョン・カンパニー	Metabolic disorders and metabolic treatments
ATE144248T1 (en) *	1992-07-01	1996-11-15	Hoechst Ag	3,4,5-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICATION OR DIAGNOSTIC AND A MEDICINE CONTAINING THEM
ES2107698T3 (en) *	1993-02-20	1997-12-01	Hoechst Ag	SUBSTITUTED BENZOILGUANIDINES, PROCEDURE FOR ITS PREPARATION, ITS USE AS A MEDICINAL PRODUCT, AS INHIBITORS OF NA + / H + CELL EXCHANGE OR AS A DIAGNOSTIC AGENT, AS WELL AS A CONTAINING MEDICINAL PRODUCT.
DE4318658A1 (en) *	1993-06-04	1994-12-08	Hoechst Ag	Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
DE4325822A1 (en) *	1993-07-31	1995-02-02	Hoechst Ag	Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
AU1882395A (en) *	1994-02-23	1995-09-11	Cambridge Neuroscience, Inc.	Blockers of ion channels and methods of use thereof
IL114670A0 (en) *	1994-08-05	1995-11-27	Fujisawa Pharmaceutical Co	Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

1996
- 1996-06-03 DE DE19622222A patent/DE19622222A1/en not_active Withdrawn
1997
- 1997-05-20 AT AT97923937T patent/ATE293965T1/en not_active IP Right Cessation
- 1997-05-20 EP EP97923937A patent/EP0918515B1/en not_active Expired - Lifetime
- 1997-05-20 NZ NZ333095A patent/NZ333095A/en unknown
- 1997-05-20 ES ES97923937T patent/ES2241049T3/en not_active Expired - Lifetime
- 1997-05-20 DK DK97923937T patent/DK0918515T3/en active
- 1997-05-20 JP JP50014498A patent/JP4527811B2/en not_active Expired - Fee Related
- 1997-05-20 TR TR1998/02505T patent/TR199802505T2/en unknown
- 1997-05-20 PL PL97330412A patent/PL189950B1/en not_active IP Right Cessation
- 1997-05-20 RU RU99100084/14A patent/RU2211032C2/en not_active IP Right Cessation
- 1997-05-20 CA CA002257299A patent/CA2257299A1/en not_active Abandoned
- 1997-05-20 IL IL12693597A patent/IL126935A0/en not_active IP Right Cessation
- 1997-05-20 DE DE59712287T patent/DE59712287D1/en not_active Expired - Lifetime
- 1997-05-20 PT PT97923937T patent/PT918515E/en unknown
- 1997-05-20 SK SK1658-98A patent/SK165898A3/en unknown
- 1997-05-20 BR BR9709516A patent/BR9709516A/en not_active Application Discontinuation
- 1997-05-20 WO PCT/EP1997/002548 patent/WO1997046226A2/en not_active Ceased
- 1997-05-20 KR KR10-1998-0709811A patent/KR100511711B1/en not_active Expired - Fee Related
- 1997-05-20 SI SI9730705T patent/SI0918515T1/en unknown
- 1997-05-20 CN CN97195194A patent/CN1221339A/en active Pending
- 1997-05-20 AU AU29576/97A patent/AU722166B2/en not_active Ceased
- 1997-05-30 AR ARP970102344A patent/AR007353A1/en unknown
- 1997-06-02 ZA ZA9704828A patent/ZA974828B/en unknown
1998
- 1998-11-24 NO NO985480A patent/NO985480L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL330412A1 (en)	1999-05-10
PL189950B1 (en)	2005-10-31
RU2211032C2 (en)	2003-08-27
SI0918515T1 (en)	2005-12-31
WO1997046226A2 (en)	1997-12-11
ES2241049T3 (en)	2005-10-16
CN1221339A (en)	1999-06-30
AU2957697A (en)	1998-01-05
JP2000506906A (en)	2000-06-06
ATE293965T1 (en)	2005-05-15
AR007353A1 (en)	1999-10-27
KR20000016240A (en)	2000-03-25
SK165898A3 (en)	1999-05-07
KR100511711B1 (en)	2005-12-26
WO1997046226A3 (en)	1998-03-05
IL126935A0 (en)	1999-09-22
NO985480L (en)	1999-01-28
DE59712287D1 (en)	2005-06-02
BR9709516A (en)	1999-08-10
AU722166B2 (en)	2000-07-20
JP4527811B2 (en)	2010-08-18
DK0918515T3 (en)	2005-08-15
NZ333095A (en)	2000-08-25
DE19622222A1 (en)	1997-12-04
EP0918515B1 (en)	2005-04-27
TR199802505T2 (en)	1999-04-21
NO985480D0 (en)	1998-11-24
PT918515E (en)	2005-06-30
CA2257299A1 (en)	1997-12-11
EP0918515A2 (en)	1999-06-02

Publication	Publication Date	Title
ZA974828B (en)	1997-12-03	Use of inhibitors of the cellular Na<+>/H<+> exchanger (NHE) for the production of a medicament for the normalization of serum lipids.
AU5706499A (en)	2000-04-03	Planar ortho-mode transducer
ZA981061B (en)	1999-08-10	Arylsulfonyl hydroxamic acid derivatives.
ZA963130B (en)	1997-10-20	Arylsulfonyl hydroxamic acid derivatives.
AU9449398A (en)	1999-05-03	Use of csaidtm compounds for the management of uterine contractions
AU8191798A (en)	1998-08-25	Arylsulfonylamino hydroxamic acid derivatives
GB9814339D0 (en)	1998-09-02	Universal database adapters
AU4124996A (en)	1996-06-19	Pressure exchanger
AU2584495A (en)	1995-11-29	Immunoassay for homocysteine
AU1566795A (en)	1995-08-01	Pharmaceutical ointment base
AU1572895A (en)	1995-08-29	Nickel shell for molds
AU2615695A (en)	1996-01-04	Hydroxamic acid derivatives
IL140387A0 (en)	2002-02-10	Remedies for hypercalcemic crisis
AU1372097A (en)	1997-07-28	Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation
AU688161B2 (en)	1998-03-05	Indicator
AU5869790A (en)	1991-01-10	Fungicidal guanidines
AU1968688A (en)	1989-01-30	Orally active antiandrogens
AU1090800A (en)	2000-03-27	Linker-assisted immunoassay for glyphosate
HUP0001879A3 (en)	2001-03-28	Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids
AU3986595A (en)	1996-07-19	Production of water-less lithographic plates
AU575536B2 (en)	1988-08-04	Lampholder
AU3184295A (en)	1996-03-07	Water-less lithographic plates
AU557483B2 (en)	1986-12-24	Fluid discharge silencer
GR1001997B (en)	1995-10-24	Cytosampler for the cervix (uteri).
AU2136895A (en)	1995-10-23	Omnidirectional exchanger for medical use